Merial Limited

Boehringer Ingelheim Animal Health USA Inc.

Centre National De La Recherche Scientifique

Université Paris—sud

Institut Gustave Roussy

Herve Poulet

Frederic Raymond David

Thierry Heidmann

Michel Joseph Bublot

Jules Maarten Minke

Frederic Reynard

Zahia Hannas-Djebbara

Sylvian Gabriel Goutebroze

Jean-Christophe Francis Audonnet

Jiansheng Yao

Denis Barral

Frédéric Reynard

David Cureton

Yu-Wei Chiang

Frederic David

Michel Bublot

The present invention relates to canine influenza virus strains, and vaccines and compositions. The present invention also relates to reagents and methods allowing their detection, methods of vaccination as well as methods of producing these reagents and vaccines.

Inactivated canine influenza vaccines and methods of making and uses thereof

The present disclosure encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs are formed by the CPV VP2 protein. Further, the disclosure broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.

Canine parvovirus (CPV) virus-like particle (VLP) vaccines and uses thereof

The present invention encompasses FCV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FCV antigens. The invention also encompasses recombinant vectors encoding and expressing FCV antigens, epitopes or immunogens which can be used to protect animals against FCV infection.

FCV recombinant vaccines and uses thereof

The present invention encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs provided by the invention are formed by the CPV VP2 protein. Further, the invention broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.

The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.

Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene

The present invention encompasses recombinant Newcastle Disease Virus-Herpesvirus vaccines or compositions. The invention encompasses recombinant NDV vectors encoding and expressing herpesvirus pathogen, antigens, proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals against disease.

Newcastle disease virus vectored herpesvirus vaccines

Immunogenic preparations and vaccines, in particular which are inactivated, effective against feline calicivirosis, based on an FCV virus strain 431 as deposited at the CNCM under the accession number CNCM I-2166, or one of its equivalents, in a veterinarily acceptable vehicle or excipient, preferably combined with FCV virus obtained from another FCV strain, in particular strain G1 as deposited at the CNCM under the accession number CNCM I-2167.

Growing community of inventors

Sainte Foy Les Lyon, France

Herve Poulet